Detection of genomic variants in BRCA1 and BRCA2 across gastric cancer patients using next generation sequencing

被引:0
|
作者
Li, Fangfang
Abdel-Maksoud, Mostafa A. [1 ,2 ]
Ullah, Tahir [3 ]
Ul Haq, Moeen [4 ]
Khan, Abdurrehman [5 ]
Olatunji, Aliu Olalekan [6 ]
Abbasi, Bakar Bin Khatab [7 ]
Saleh, Ibrahim A. [8 ]
Rather, Mehak Nabi [9 ]
Al-Hawadi, Jehad S. [8 ]
Zomot, Naser [8 ]
Almutairi, Saeedah Musaed
Naz, Rida [10 ]
机构
[1] Jiaozhou Cent Hosp Qingdao, Dept Gastroenterol, Qingdao 266300, Shandong, Peoples R China
[2] King Saud Univ, Coll Sci, Bot & Microbiol Dept, POB 2455, Riyadh 11451, Saudi Arabia
[3] Bannu Med Coll, Bannu 28100, Pakistan
[4] Gomal Med Coll, Dera Ismail Khan 29050, Pakistan
[5] Gomal Med Coll, Med Dept, Dera Ismail Khan, Pakistan
[6] Inst Univ Toledo, Dept Med Microbiol & Immunol, Toledo, OH 43606 USA
[7] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA
[8] Zarqa Univ, Fac Sci, Zarqa 13110, Jordan
[9] North End Hosp, Taper Wari Pora, J&K, India
[10] Reg Blood Ctr, Dera Ismail Khan 29050, Pakistan
来源
关键词
Gastric cancer; NGS; BRCA genes; NEGATIVE BREAST-CANCER; GENE-EXPRESSION; DNA-REPAIR; MUTATIONS; THERAPY; PROGNOSIS; CARCINOMA; PATTERNS; SURVIVAL; PLATFORM;
D O I
10.62347/MRIE2131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To explore the landscape of BRCA1/2 mutations in gastric cancer patients. Methods: Next- generation sequencing (NGS), Sanger sequencing, reverse transcription quantitative polymerase chain reaction (RTqPCR), Immunohistochemistry, The Cancer Genome Atlas (TCGA), gnomAD, and DAVID. Results: With 95% of bases boasting a phred score surpassing 30 and a minimum coverage depth of 500X, our NGS approach ensures high- quality data acquisition. Analyzing BRCA1 and BRCA2 sequences revealed 11 and 4 mutations, respectively, with one pathogenic mutation identified in each gene. This emphasizes the prominence of BRCA1 mutations in gastric cancer. Sanger sequencing validation confirmed the presence of pathogenic mutations in select cases, consolidating our findings. Frequency analysis utilizing the gnomAD database elucidated the rarity of these mutations in the Asian population, underscoring their uniqueness. Exploring TCGA data further corroborated this rarity, emphasizing the distinctive nature of these mutations in gastric cancer. RT-qPCR analysis unveiled a significant reduction in BRCA1/2 expression in samples harboring pathogenic mutations, hinting at their potential role in down-regulating gene expression. Immunohistochemistry confirmed diminished protein expression in samples with pathogenic mutations, solidifying our observations. Kaplan-Meier survival analysis demonstrated significantly poorer survival outcomes for patients with pathogenic BRCA1/2 mutations compared to those without, emphasizing their potential role in prognosis. Additionally, KEGG pathway analysis highlighted the involvement of BRCA1/2 in critical cancer- associated pathways, emphasizingtheir role in tumorigenesis. Conclusion: Our comprehensive findings underscore the clinical significance of BRCA1/2 mutations in gastric cancer, advocating for further research to elucidate their mechanistic implications and therapeutic opportunities.
引用
收藏
页码:7898 / 7910
页数:13
相关论文
共 50 条
  • [41] Unveiling pathogenic mutations in BRCA1 and BRCA2 genes across head and neck squamous cell carcinoma patients via next generation sequencing
    Wei, Xiaotong
    Tian, Zhizhengrong
    Zhao, Fengyun
    Sun, Anjun
    Zhao, Shujuan
    Jamil, Muhammad
    Yan, Wei
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12): : 6099 - 6112
  • [42] BRCA1 and BRCA2 in Indian Breast Cancer Patients
    Saxena, Sunita
    Szabo, Csilla I.
    Chopin, Sandrine
    Barjhoux, Laure
    Sinilnikova, Olga
    Lenoir, Gilbert
    Goldgar, David E.
    Bhatanager, Dinesh
    HUMAN MUTATION, 2002, 20 (06) : 473 - 474
  • [43] BRCA1 and BRCA2 cancer risks
    Antoniou, Antonis C.
    Pharoah, Paul D. P.
    Easton, Douglas F.
    Evans, D. Gareth
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (20) : 3312 - 3313
  • [44] BRCA1 and BRCA2 in breast cancer
    Yang, XH
    Lippman, ME
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 54 (01) : 1 - 10
  • [45] BRCA1 and BRCA2 in breast cancer
    Lee, WH
    Boyer, TG
    LANCET, 2001, : S5 - S5
  • [46] DETECTION OF LARGE GENOMIC REARRANGEMENTS IN BRCA1/BRCA2: A RETROSPECTIVE STUDY
    Custodio, Sonia
    Rodrigues, Raquel
    Medeira, Ana
    Dupont, Juliette
    Dias, Patricia
    Rodrigues, Marcia
    Soeiro e Sa, Mariana
    Travessa, Andre
    Silva, Raquel G.
    Soares, Marta P.
    Carvalho, Celia
    Custodio, Noelia
    Carmo-Fonseca, Maria
    Sousa, Ana
    Sousa, Ana B.
    MEDICINE, 2025, 104 (04)
  • [47] BRCA1 and BRCA2 in breast cancer
    Xiaohong Yang
    Marc E. Lippman
    Breast Cancer Research and Treatment, 1999, 54 : 1 - 10
  • [48] Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing
    Wu, Heming
    Wang, Qiuming
    Guo, Xuemin
    Liu, Qinghua
    Zhang, Qunji
    Huang, Qingyan
    Yu, Zhikang
    HUMAN HEREDITY, 2020, 84 (4-5) : 160 - 169
  • [49] Detection of BRCA1 and BRCA2 variants in circulating free DNA by using a commercial kit
    Capone, G. L.
    Putignano, A. L.
    Patuelli, A.
    Paganini, I.
    Sestini, R.
    Gensini, F.
    Marozza, A.
    Porfirio, B.
    Papi, L.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 399 - 400
  • [50] Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
    Edaily, Sarah
    Abdel-Razeq, Hikmat
    ONCOTARGETS AND THERAPY, 2022, 15 : 815 - 826